Search


Current filters:


Start a new search
Add filters:

Use filters to refine the search results.


Results 1-10 of 34 (Search time: 0.002 seconds).
Item hits:
PreviewIssue DateTitleAuthor(s)
2014Stress ulceration: prevalence, pathology and association with adverse outcomesPlummer, M.; Blaser, A.; Deane, A.
2014Implementing evidence-based recommended practices for the management of patients with mild traumatic brain injuries in Australian emergency care departments: Study protocol for a cluster randomised controlled trialBosch, M.; McKenzie, J.E.; Mortimer, D.; Tavender, E.J.; Francis, J.J.; Brennan, S.E.; Knott, J.C.; Ponsford, J.L.; Pearce, A.; O'Connor, D.A.; Grimshaw, J.M.; Rosenfeld, J.V.; Gruen, R.L.; Green, S.E.; Bayley, M.; Buchan, H.; Cameron, P.; Cooper, J.; Ellis, N.; Fitzgerald, M.; et al.
2014Continuous subcutaneous hydrocortisone infusion therapy in Addison's disease: a randomized, placebo-controlled clinical trialGagliardi, L.; Nenke, M.; Thynne, T.; von der Borch, J.; Rankin, W.; Henley, D.; Sorbello, J.; Inder, W.; Torpy, D.
2014Merkel cell carcinoma of the eyelid management and prognosisHerbert, H.; Sun, M.; Selva, D.; Fernando, B.; Saleh, G.; Beaconsfield, M.; Collin, R.; Uddin, J.; Meligonis, G.; Leatherbarrow, B.; Ataullah, S.; Irion, L.; McLean, C.; Huilgol, S.; Davis, G.; Sullivan, T.
2014Impact of baseline lipoprotein and C-reactive protein levels on coronary atheroma regression following high-intensity statin therapyPuri, R.; Nissen, S.; Shao, M.; Uno, K.; Kataoka, Y.; Kapadia, S.; Tuzcu, E.; Nicholls, S.
2014The relationship between rash, tumour KRAS mutation status and clinical and quality of life outcomes in patients with advanced colorectal cancer treated with cetuximab in the NCIC CTG/AGITG CO.17Sommeijer, D.; Karapetis, C.; Zalcberg, J.; Tu, D.; Jonker, D.; Simes, J.; Tebbutt, N.; Yip, D.; Price, T.; O'Callaghan, C.
2014Magnesium sulphate for preventing preterm birth in threatened preterm labourCrowther, C.; Brown, J.; McKinlay, C.; Middleton, P.
2014Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice dailyHughes, T.; Hochhaus, A.; Kantarjian, H.; Cervantes, F.; Guilhot, F.; Niederwieser, D.; Le Coutre, P.; Rosti, G.; Ossenkoppele, G.; Lobo, C.; Shibayama, H.; Fan, X.; Menssen, H.; Kemp, C.; Larson, R.; Saglio, G.
2014Impact of reirradiation of painful osseous metastases on quality of life and function: a secondary analysis of the NCIC CTG SC.20 randomized trialChow, E.; Meyer, R.; Chen, B.; van der Linden, Y.; Roos, D.; Hartsell, W.; Hoskin, P.; Wu, J.; Nabid, A.; Tissing-Tan, C.; Oei, B.; Babington, S.; Demas, W.; Wilson, C.; Wong, R.; Brundage, M.
2014Gastrointestinal: rare and almost fatal case of upper gastrointestinal bleedingHossain, M.; Fernando, J.; Nordeen, N.; Raju, D.; Cechic, G.; Raju, S.; Singh, R.